Abstract:Purpose: Metabolomics has attracted attention as a new method for understanding the molecular mechanisms of psychiatric disorders. Current metabolomics technology allows us to measure over hundreds of metabolites at a time and is a useful indicator of the consequences of complex and continuous changes in metabolic profiles due to the execution of genomic information and external factors of biological activity. Therefore, metabolomics is imperative to the discovery of biomarkers and mechanisms associated with pathophysiological processes. In this study, we investigated metabolites changes in hospitalized patients with chronic schizophrenia compared to that in healthy controls, and examined the correlations between the metabolites and psychiatric symptoms. Patients and Methods: Thirty patients with schizophrenia and ten healthy controls participated in this study between September 2019 and June 2020. The mean duration of disease in patients with schizophrenia was 26 years. Clinical and neuropsychiatric symptoms of patients with schizophrenia were assessed using the Positive and Negative Syndrome Scale (PANSS). Metabolomics was conducted using Capillary Electrophoresis Fourier Transform Mass Spectrometry (CE-FTMS), using serum samples from patients with schizophrenia and healthy controls. Metabolomics assigned a candidate compound to the 446 (cation 279, anion 167) peaks. Hierarchical cluster analysis (HCA), principal component analysis (PCA), logistic regression analysis, receiver operating characteristic (ROC) analysis, and linear regression analysis were used to analyze the metabolites changes, identifying the disease and the relationship between metabolites and psychiatric symptoms. Results: HCA showed that approximately 60% of metabolites had lower peak values in patients with schizophrenia than in healthy controls. Glutamate metabolism and the urea cycle had the highest proportions in the metabolic pathway, which decreased in patients with schizophrenia. PCA showed a clear separation between patients with schizophrenia and healthy controls in the first principal component (the contribution ratio of the first principal component was 15.9%). Logistic regression analysis suggested that the first principal component was a predictor of disease (odds = 1.36, 95%CI = 1.11–1.67, p = 0.0032). ROC analysis showed a sensitivity of 93% and a specificity of 100% for the diagnosis of schizophrenia with a cut-off value of the first principal component; −3.33 (AUC = 0.95). We extracted the high factor loading for the first principal component. Gamma-glutamyl-valine (γ-Glu-Val) was significantly negatively correlated with PANSS total scores ( r = −0.45, p = 0.012) and PANSS general scores ( r = −0.49, p = 0.0055). Gamma-glutamyl-phenylalanine (γ-Glu-Phe) was significantly negatively correlated with PANSS total score ( r = −0.40, p = 0.031) and PANSS general score ( r = −0.41, p = 0.025). Tetrahydrouridine was significantly positively correlated with PANSS negative scores ( r = 0.53, p = 0.0061). Conclusion: Metabolites changes in hospitalized patients with chronic schizophrenia showed extensive and generalized declines. Glutamate metabolism and the urea cycle had the highest proportions in the metabolic pathway, which decreased in the schizophrenia group. Metabolomic analysis was useful to identify chronic schizophrenia. Some glutamate compound metabolites had a relationship with psychiatric symptoms.

Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: A targeted metabolomics study

Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia.

Multiomics Analyses Reveal Microbiome–Gut–Brain Crosstalk Centered on Aberrant Gamma-Aminobutyric Acid and Tryptophan Metabolism in Drug-Naïve Patients with First-Episode Schizophrenia

Alterations of Eicosanoids and Related Mediators in Patients with Schizophrenia.

Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia.

Characterising phospholipids and free fatty acids in patients with schizophrenia: A case-control study

Dysregulation of Serum Exosomal Lipid Metabolism in Schizophrenia: A Biomarker Perspective

The identification of novel schizophrenia-related metabolites using untargeted lipidomics

Metabolomic Analysis Reveals Metabolic Disturbance in the Cortex and Hippocampus of Subchronic Mk-801 Treated Rats

Detection of Metabolites in the White Matter of Frontal Lobes and Hippocampus with Proton in First‐episode Treatment‐naïve Schizophrenia Patients

Exploring the relationship between lipid metabolism and cognition in individuals living with stable-phase Schizophrenia: a small cross-sectional study using Olink proteomics analysis

Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case–control study

LC–HRMS Lipidomic Fingerprints in Serbian Cohort of Schizophrenia Patients

Altered MANF and RYR2 concentrations associated with hypolipidemia in the serum of patients with schizophrenia

Plasma metabolic alterations and potential biomarkers in individuals at clinical high risk for psychosis

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a <SUP>1</SUP>H MRS study

A Metabolomics Study of Serum in Hospitalized Patients With Chronic Schizophrenia

Association Between Lipid Metabolism and Cognitive Function in Patients with Schizophrenia

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a 1 H MRS study

Metabolomic Profiling to Identify Potential Serum Biomarkers for Schizophrenia and Risperidone Action.

Serum metabolic profile evidence for relationship between schizophrenia and depression: An untargeted metabolomics